The β-lactamase inhibitor avibactam (NXL104) does not induce ampC β -lactamase in Enterobacter cloacae

Christine Miossec, Monique Claudon, Premavathy Levasseur, Michael T Black Novexel, Romainville, France Abstract: Induction of ampC β-lactamase expression can often compromise antibiotic treatment and is triggered by several β-lactams (such as cefoxitin and imipenem) and by the &...

Full description

Bibliographic Details
Main Authors: Miossec C, Claudon M, Levasseur P, Black MT
Format: Article
Language:English
Published: Dove Medical Press 2013-12-01
Series:Infection and Drug Resistance
Online Access:http://www.dovepress.com/the-beta-lactamase-inhibitor-avibactam-nxl104-does-not-induce-ampc-bet-a15161
Description
Summary:Christine Miossec, Monique Claudon, Premavathy Levasseur, Michael T Black Novexel, Romainville, France Abstract: Induction of ampC β-lactamase expression can often compromise antibiotic treatment and is triggered by several β-lactams (such as cefoxitin and imipenem) and by the β-lactamase inhibitor clavulanic acid. The novel β-lactamase inhibitor avibactam (NXL104) is a potent inhibitor of both class A and class C enzymes. The potential of avibactam for induction of ampC expression in Enterobacter cloacae was investigated by ampC messenger ribonucleic acid quantitation. Cefoxitin and clavulanic acid were confirmed as ampC inducers, whereas avibactam was found to exert no effect on ampC expression. Thus, avibactam is unlikely to diminish the activity of any partner β-lactam antibiotic against AmpC-producing organisms. Keywords: β-lactamase, ampC, induction, NXL104, avibactam
ISSN:1178-6973